The prevalence of mismatch repair deficiency in ovarian cancer: a systematic review and meta-analysis
One of the many disappointments in the treatment of ovarian cancer has been the failure of immunotherapy. For other cancers, most significantly melanoma, immune therapy in the form of checkpoint inhibition with drugs such as Keytruda has been game changing. Thus far this has not been true for ovarian cancer.
Checkpoint inhibition is most effective for cancers with defective DNA repair mediated through a process called Mismatch Repair deficiency (MMR). Some ovarian cancer demonstrates MMR.
This study looks at all the available published information to determine the prevalence of MMR. Results from the review show MMR to be most likely for women with endometrioid ovarian cancer or cancer due to Lynch syndrome, with an overall prevalence of about 7% of all ovarian cancer. The authors note that MMR testing may guide precision immune therapy to those most likely to respond.
No comments:
Post a Comment